Panobinostat for the treatment of multiple myeloma

Bibliography

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364(11):1046-60
   PubMed Web of Science ®Google Scholar
• SEER cancer statistics factsheets: myeloma. National Cancer Institute; 2014. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html [Cited 5 May 2014]
   Google Scholar
• Mitsiades CS, Davies FE, Laubach JP, et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011;29(14):1916-23
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111(5):2516-20
   PubMed Web of Science ®Google Scholar
• Harousseau JL. How to select among available options for the treatment of multiple myeloma. Ann Oncol 2012;23(Suppl 10):x334-8
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014;32(6):587-600
   PubMed Web of Science ®Google Scholar
• Kale AJ, Moore BS. Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem 2012;55(23):10317-27
   PubMed Web of Science ®Google Scholar
• Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 2013;54(4):683-7
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120(14):2817-25
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014;123(12):1826-32
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Fabre C, Lonial S, Richardson PG. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clin Lymphoma Myeloma Leuk 2013;13(4):370-6
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades CS, Laubach JP, et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013;37(7):829-37
   PubMed Web of Science ®Google Scholar
• Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014;28(3):525-42
   PubMed Web of Science ®Google Scholar
• Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012;90(1):85-94
   PubMed Web of Science ®Google Scholar
• Neri P, Bahlis NJ, Lonial S. Panobinostat for the treatment of multiple myeloma. Expert Opin Investig Drugs 2012;21(5):733-47
   PubMed Web of Science ®Google Scholar
• Mithraprabhu S, Khong T, Jones SS, Spencer A. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol 2013;162(4):559-62
   PubMed Web of Science ®Google Scholar
• Raje N, Vogl DT, Hari PN, et al. ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with bortezomib in patients with multiple myeloma (MM). Oral presenation (ASH meeting) and abstract (ASCO meeting). 2013
   Google Scholar
• Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 2013;14(11):1129-40
   PubMed Web of Science ®Google Scholar
• Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15(16):5250-7
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Quach H, Link E, et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. 2011
   Google Scholar
• San-Miguel JF, de Moraes Hungria VT, Yoon S-S, et al. Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1). Oral presenation (ASH meeting) and abstract (ASCO meeting). Am Soc Clin Oncol 2012;2012
   Google Scholar
• Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009;280(2):233-41
   PubMed Web of Science ®Google Scholar
• Anne M, Sammartino D, Barginear MF, Budman D. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther 2013;6:1613-24
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013;27(8):1628-36
   PubMed Web of Science ®Google Scholar
• Oki Y, Copeland A, Younes A. Clinical development of panobinostat in classical Hodgkin’s lymphoma. Expert Rev Hematol 2011;4(3):245-52
   PubMed Web of Science ®Google Scholar
• Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010;28(Suppl 1):S3-20
   PubMed Web of Science ®Google Scholar
• Clive S, Woo MM, Nydam T, et al. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol 2012;70(4):513-22
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Frank R, Dandamudi UB, et al. The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 2012;69(2):555-62
   PubMed Web of Science ®Google Scholar
• Savelieva M, Woo MM, Weber HA, et al. Population pharmacokinetics of panobinostat (LBH589) in patients with advanced solid tumors and hematologic malignancies following intravenous and oral administration. Am Soc Hematol 2009;2009
   Google Scholar
• Hamberg P, Woo MM, Chen LC, et al. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 2011;68(3):805-13
   PubMed Web of Science ®Google Scholar
• Berenson JR, Hilger JD, Yellin O, et al. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol 2014;93(1):89-98
   PubMed Web of Science ®Google Scholar
• Offidani M, Polloni C, Cavallo F, et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 2012;53(9):1722-7
   PubMed Web of Science ®Google Scholar
• Mateos M, Spencer A, Taylor K, et al. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). J Clin Oncol 2010;28(15S):8030
   Google Scholar
• Wolf JL, Siegel D, Goldschmidt H, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 2012;53(9):1820-3
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Richardson PG, Gunther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2013;31(29):3696-703
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013;122(14):2331-7
   PubMed Web of Science ®Google Scholar
• Richardson PG, Hungria VTM, Yoon S-S, et al. Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2014 ASCO Annual Meeting Abstracts 2014 June 11 2014;32(15 Suppl):abstract 8510^; May 20 Supplement
   Google Scholar
• Berdeja JG, Hart L, Lamar R, et al. Phase I/II study of panobinostat and carfilzomib in patients (pts) with relapsed or refractory multiple myeloma (MM), interim phase 1 safety analysis. 54th ASH Annual Meeting and Exposition; Atlanta, GA; 2012
   Google Scholar
• Shah JJ, Thomas SK, Weber DM, et al. Phase 1/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and/or refractory multiple myeloma. 54th ASH Annual Meeting and Exposition; Atlanta, GA; 2012
   Google Scholar
• Kaufman JL, Zimmerman T, Rosenbaum CA, et al. Phase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: a multiple myeloma research consortium (MMRC) clinical trial. 56th ASH Annual Meeting and Exposition; San Francisco, CA; 2014
   Google Scholar
• San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15:1195-206
   PubMed Web of Science ®Google Scholar
• Giver CR, Jaye DL, Waller EK, Lonial S. Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin. Exp Hematol 2012;40(2):95-6
   PubMed Web of Science ®Google Scholar
• Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119(11):2579-89
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiao J, Suzek TO, et al. PubChem’s bioassay database. Nucleic Acids Res 2012;40(Database issue):D400-12
   PubMed Web of Science ®Google Scholar